allogeneic mesenchymal stem cells

Phase 2Cell therapy

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

allogeneic mesenchymal stem cells is one of 153 small molecule programs targeting Ischemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

152

Competitors

Pipeline

Status by Indication[3][1]

Indication

IschemiaActive, not recruiting

Urinary IncontinenceActive, not recruiting

Systemic SclerosisActive, not recruiting

Diabetic FootActive, not recruiting

CirrhosisActive, not recruiting

IschemiaPhase 2

Active, not recruiting

Urinary IncontinencePhase 1

Active, not recruiting

Systemic SclerosisPhase 1/Phase 2

Active, not recruiting

Diabetic FootPhase 1/Phase 2

Active, not recruiting

CirrhosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

252 competitors in Cirrhosis

#DrugCompanyPhaseTrials

allogeneic mesenchymal stem cells

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2

1 2

Proamatine

Takeda

Preclinical

9 3

Crestor

AstraZeneca

Preclinical

2 4

Revia

Teva

Preclinical

1 5

Dobutrex

Eli Lilly

Preclinical

1 6

Azulfidine

Pfizer

Preclinical

1 7

HEPCLUDEX

Gilead

Preclinical

1 8

Farxiga

AstraZeneca

Preclinical

1 9

Coreg

Akero Therapeutics

Preclinical

6 10

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Urinary incontinence1 trial

Allogeneic Use of Expanded Mesenchymal Stem Cells Derived From Adipose Tissue (HC106), Female Urinary Incontinence Women Over 50 Years Old

Recruiting·IInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz·Phase 1·NCT06738576·60 enrolled

Ischemia1 trial

A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers Disease

Completed·SStempeutics Research Pvt Ltd·Phase 2·NCT01484574·90 enrolled

Cirrhosis1 trial

Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis

Completed·SStempeutics Research Pvt Ltd·Phase 2·NCT01591200·40 enrolled

Primary Sjögren's Syndrome (pSS)1 trial

Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS)

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 1/2·NCT00953485·20 enrolled

Systemic Sclerosis1 trial

Allogeneic Mesenchymal Stem Cells Transplantation for Systemic Sclerosis (SSc)

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 1/2·NCT00962923·20 enrolled

1 more indication

Diabetic Foot1 trial

Safety and Efficacy of Stem Cells for Diabetic Foot Ulcer

Not yet recruiting·SSupergenics Life Science Sdn. Bhd.·Phase 1/2·NCT06231771·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for allogeneic mesenchymal stem cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — allogeneic mesenchymal stem cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for allogeneic mesenchymal stem cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

allogeneic mesenchymal stem cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Urinary incontinence1 trial

Ischemia1 trial

Cirrhosis1 trial

Primary Sjögren's Syndrome (pSS)1 trial

Systemic Sclerosis1 trial

Diabetic Foot1 trial

References

Drug Info

Quick Facts

Related News